Stock GILD GILEAD SCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Gilead Sciences, Inc.

Equities

GILD

US3755581036

Real-time Estimate Cboe BZX
Other stock markets
 14:13:55 2024-05-08 EDT 		5-day change 1st Jan Change
65 USD -0.70% Intraday chart for Gilead Sciences, Inc. -0.82% -19.79%
05-07 Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates MT
05-02 UBS Adjusts Price Target on Gilead Sciences to $70 From $75, Maintains Neutral Rating MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates
MT
Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approve Biktarvy® Label Update With Data for Pregnant Adults With HIV
CI
News Highlights : Top Company News of the Day - Friday at 1 AM ET
DJ
News Highlights : Top Company News of the Day - Thursday at 11 PM ET
DJ
News Highlights : Top Company News of the Day - Thursday at 9 PM ET
DJ
News Highlights : Top Company News of the Day - Thursday at 5 PM ET
DJ
News Highlights : Top Company News of the Day - Thursday at 7 PM ET
DJ
Gilead Sciences Q1 Tops Estimates, Updates Outlook
MT
Gilead Sciences Posts Higher 1Q Sales, Swings to Loss on Charges
DJ
(GILD) GILEAD SCIENCES Forecasts Fiscal Year 2024 EPS Range $3.45 - $3.85
MT
Earnings Flash (GILD) GILEAD SCIENCES Reports Q1 Revenue $6.69B, vs. Street Est of $6.348B
MT
Tranche Update on Gilead Sciences, Inc.'s Equity Buyback Plan announced on February 25, 2020.
CI
Gilead Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Gilead posts quarterly loss, revenue rises 5%
RE
Gilead Sciences, Inc. Revises Earnings Guidance for the Full Year 2024
CI
Gilead Sciences, Inc. Declares a Dividend for the Second Quarter of 2024, Payable on June 27, 2024
CI
Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says
MT
US FDA mandates label updates on CAR-T cancer therapies
RE
Nurix Therapeutics, Gilead Sciences Extend Research Collaboration By 2 Years
MT
Nurix Therapeutics, Gilead Sciences Extend Strategic Collaboration
DJ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GILD Stock
  4. News Gilead Sciences, Inc.
  5. Highlights
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW